Isolation and characterization of adociavirin, a novel HIV-inhibitory protein from the sponge Adocia sp.1Part 51 in the series `Anti-HIV Natural Products'; for part 50, see Fuller, R.W., Westergaard, C.K., Collins, J.W., Cardellina, J.H. II and Boyd, M.R. (1998) J. Nat. Prod. (submitted).1  by O'Keefe, Barry R et al.
Isolation and characterization of adociavirin, a novel HIV-inhibitory
protein from the sponge Adocia sp.
Barry R. O’Keefea, Tolga Erim1;a, John A. Beutlera, John H. Cardellina IIa,
Robert J. Gulakowskia, Benjamin L. Kreppsa, James B. McMahona,
Raymond C. Sowder IIb, Donald G. Johnsonb, Robert W. Buckheit Jr.c, Susan Hallidayc,
Michael R. Boyda;*
aLaboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis,
Frederick Cancer Research and Development Center, Bldg 1052, Rm. 121, Frederick, MD 21702-1201, USA
bAIDS Vaccine Program, S.A.I.C.-Frederick, NCI-Frederick Cancer Research and Development Center, Frederick, MD 21702-1201, USA
cSouthern Research Institute, Frederick Research Center, Frederick, MD 21701, USA
Received 16 April 1998; revised version received 9 June 1998
Abstract Aqueous extracts of the New Zealand sponge Adocia
sp. (Haplosclerida) displayed potent anticytopathic activity in
CEM-SS cells infected with HIV-1. Protein fractions of the
extract bound both to the viral coat protein gp120 and to the
cellular receptor CD4, but not to other tested proteins. The
purified active protein, named adociavirin, was characterized by
isoelectric focusing, amino acid analysis, MALDI-TOF mass
spectrometry and N-terminal sequencing. Adociavirin, a di-
sulfide-linked homodimer with a native molecular weight of 37
kDa, was active against diverse strains and isolates of HIV-1, as
well as HIV-2, with EC50 values ranging from 0.4 nM to s 400
nM. The anti-HIV potency of adociavirin appears dependent on
host cell type, with macrophage cultures being the most sensitive
and peripheral blood lymphocytes the most resistant.
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1. Introduction
As part of the search for new drug candidates for the treat-
ment of AIDS, the National Cancer Institute has carried out a
screening program to test natural product extracts for their
ability to protect T-lymphoblastoid cells from human immu-
node¢ciency virus (HIV-1)-induced cell killing [1,2]. In addi-
tion to this cell-based assay system, secondary assays devel-
oped for speci¢c binding to the viral coat protein gp120 and
to the cellular receptor CD4 were instituted within the Labo-
ratory of Drug Discovery Research and Development to pri-
oritize further the protein fractions of marine extracts. Using
these two prioritization methods, as well as previously de-
scribed dereplication procedures for antiviral extracts [3,4],
aqueous extracts of the New Zealand sponge Adocia sp. (Hap-
losclerida) were selected for bioassay-guided fractionation of
their HIV-inhibitory constituents.
Earlier studies on organic extracts of the sponge genus Ado-
cia have resulted in the identi¢cation of several classes of bio-
logically active compounds, including diterpene isocyanides
[5,6] and xestoquinone/halenaquinone derivatives [7]. Previous
work in our laboratory has shown that the aqueous extracts
of a variety of organisms are a productive source of novel
proteins and peptides with anti-HIV activity [8,9]. Here we
report the isolation and characterization of a novel protein
from an aqueous extract of the sponge Adocia sp. with potent
inhibitory activity against HIV-induced cytopathicity.
2. Materials and methods
2.1. Sponge material
A sample of the sponge Adocia sp. (670 g) was collected at a depth
of 14 m on a rocky reef in Ocean Bay, 30 m o¡shore of Chatham
Island, New Zealand. A taxonomic voucher specimen (sample number
Q66D293) has been deposited at the Smithsonian Institution Sorting
Center, Suitland, MD, USA.
2.2. Protein determinations
Protein content in various samples was determined by colorimetric
assay using the Bio-Rad protein assay system with bovine Q-globulin
as the standard according to the procedures of Bradford [10].
2.3. Sulfated polysaccharide determinations
To determine the presence or absence of sulfated polysaccharides in
aqueous fractions of Adocia sp., samples were tested using the cationic
dye toluidine blue O and analyzed for absorbance at 620 nm as de-
scribed previously [3,11].
2.4. Bioassay for monitoring the puri¢cation of adociavirin
CEM-SS cells [12] were maintained in RPMI 1640 medium without
phenol red and supplemented with 5% fetal bovine serum (BioWhit-
taker, Walkersville, MD), 2 mM L-glutamine (BioWhittaker) and 50
mg/ml gentamicin (BioWhittaker) (complete medium). Exponentially
growing cells were washed, resuspended in complete medium, and a
50 Wl aliquot containing 5000 cells was added to individual wells of a
round bottom, 96-well, microtiter plate containing serial dilutions of
adociavirin in a volume of 100 Wl of medium. Stock supernatants of
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HIV-1RF were diluted in complete medium to yield a multiplicity of
infection (MOI) of 0.8 (80^90% cell kill in 6 days) and a 50 Wl aliquot
was added to appropriate wells. Plates were incubated for 6 days at
37‡C and then assayed for cellular viability, metabolic activity, DNA
content, p24 antigen production, supernatant reverse transcriptase
activity and the synthesis of infectious virions as previously described
[13].
2.5. Delayed addition of adociavirin to HIV-1RF -infected cells
CEM-SS cells were plated into individual wells of a 96-well micro-
titer plate at a density of 5000 cells/well in 50 Wl of medium. Diluted
HIV-1RF stock supernatants (50 Wl) were added to appropriate wells
to yield an MOI of 1.0. At various times after the addition of virus, a
100 Wl aliquot of 2.5 Wg/ml adociavirin was added to multiple wells.
After a total of 6 days incubation, cellular viability was assessed using
the XTT assay as previously described [13].
2.6. E¡ect of adociavirin on cell-cell fusion
Uninfected CEM-SS cells (1U105/50 Wl) and CEM/HIV-1RF-in-
fected cells (1U103/50 Wl) were incubated together, in £at-bottomed,
96-well microtiter plates in the presence of various concentrations of
adociavirin (100 Wl) or 100 Wl of complete medium alone. The plates
were incubated for 96 h and the number of syncytia quantitated mi-
croscopically. Each experimental condition consisted of six replicate
samples.
2.7. Assays for anti-HIV activity in fresh human cells
Descriptions and sources of the T-tropic virus strains, primary iso-
lates and cell lines have been previously published [14,15]. The HIV-1
dual-tropic isolate 89.6 [16] and the M-tropic isolates Ba-L [17] and
Ada-M [18] were obtained from the National Institute of Allergy and
Infectious Diseases (NIAID) AIDS Research and Reference Program.
The M-tropic isolate SKLA was obtained from a pediatric patient of
the University of Alabama (Birmingham) pediatric AIDS clinic by
cocultivation of the patient’s peripheral blood mononuclear cells
with uninfected normal donor cells ; the virus pool was expanded
and frozen in liquid nitrogen after one passage.
For antiviral assays, peripheral blood lymphocytes (PBL) and mac-
rophages (MAC) were isolated as necessary following Ficoll-Hypaque
centrifugation as described elsewhere [19].
2.8. Stability tests
Crude protein samples from Adocia sp. were taken up in 50 mM
sodium phosphate bu¡er (pH 7.5) augmented with 0.02% NaN3 and
one of the following components: 10 mM EDTA, 5 mM DTT, and
either 1% or 10% glycerol. The ¢nal concentration of the protein in
solution was 50 Wg/ml. Samples treated with glycerol were separated
into three aliquots and stored at 320‡C, 4‡C or room temperature for
a period of 14 days prior to assay.
To determine pH stability, protein samples, puri¢ed through etha-
nolic precipitation and ammonium sulfate precipitation, were taken
up in 50 mM sodium phosphate bu¡er titrated to the following pH
values: 4.0, 5.0, 6.0, 6.5, 7.0, 7.5, 8.0 and 9.0, and were stored at 4‡C
for 24 h prior to assay.
2.9. Protein puri¢cation
2.9.1. Ethanol precipitation. The removal of sulfated polysaccha-
rides from crude aqueous extracts was performed essentially as re-
ported previously [3]. Brie£y, an equal volume of absolute ethanol
was added to Adocia sp. aqueous extract that had been dissolved in
distilled deionized water at a concentration of 50 mg/ml. The etha-
nolic suspension was allowed to precipitate overnight at 320‡C and
then centrifuged at 3000 rpm for 60 min. The pellet was set aside and
the supernatant was evaporated under vacuum to dryness prior to use
in later puri¢cation steps.
2.9.2. Ammonium sulfate precipitation. Freeze-dried ethanolic
supernatants from Adocia sp. were taken up in 25 mM sodium phos-
phate bu¡er (pH 7.5) at a concentration of 50 mg/ml and maintained
on ice. Crystalline ammonium sulfate (Sigma, molecular biology
grade) was added to the solution to bring the ¢nal concentration to
30% saturation. The mixture was allowed to precipitate on ice for 120
min and was then centrifuged at 3000 rpm for 60 min. The pellets
were set aside and the supernatant was then brought to 55% satura-
tion with ammonium sulfate followed again by precipitation and cen-
trifugation. Finally, the second pellets were saved and the supernatant
was brought to 75% saturation with ammonium sulfate; all other
steps were repeated as above.
2.9.3. Sephadex G-100 gel permeation. Freeze-dried ethanolic
supernatants from Adocia sp. were taken up in 50 mM sodium phos-
phate bu¡er (pH 7.5) augmented with 0.4 M NaCl and 0.02% NaN3.
The samples were placed on a Sephadex G-100 column (2.5U50 cm,
Sigma) and eluted with the same bu¡er at a £ow rate of 2.5 ml/min.
The eluant was monitored at 280 nm and fractions were taken each
minute. Active fractions were concentrated by ammonium sulfate pre-
cipitation.
2.9.4. Anion exchange chromatography. Active fractions from the
Sephadex G-100 column were ¢rst concentrated and desalted by ultra-
¢ltration on a YM-10 membrane (10 kDa molecular weight limit,
Amicon) into the starting bu¡er (25 mM sodium phosphate, pH
7.5). The desalted fractions were then injected onto a Poros HQ col-
umn (5U100 mm, Perseptive Biosystems) pre-equilibrated with the
same starting bu¡er. The column was eluted at a £ow rate of 2.0
ml/min using the following gradient: (1) 5 column volumes (CV, equal
to 1.66 ml) of the starting bu¡er; (2) 6 CV of 0.1 M NaCl in the
starting bu¡er; (3) 0.1^0.4 M NaCl over 20 CV; (4) 0.4 M NaCl for
4 CV; (5) 0.4^1.0 M NaCl over 4 CV; (6) 1.0 M NaCl for 5 CV. The
eluate was monitored for both conductivity and absorbance (210 and
280 nm). Fractions were collected every 3 ml.
2.9.5. Hydrophobic interaction chromatography. Active fractions
from the Poros HQ column were combined and concentrated on
YM-10 membranes and then brought up to a concentration of 1.5
M ammonium sulfate. This protein solution was then injected onto a
Poros PE column (5U100 mm, Perseptive Biosystems) pre-equili-
brated with a starting bu¡er of 50 mM sodium phosphate, 1.5 M
(NH4)2SO4, pH 7.5. The column was then eluted at a £ow rate of
5 ml/min over the following gradient: (1) 12 CV of the starting bu¡er;
(2) 1.5^0 M (NH4)2SO4 over 75 CV; (3) 0 M (NH4)2SO4 for 15 CV.
The eluate was monitored for both conductivity and absorbance (210
and 280 nm). Fractions were collected every 5 ml.
2.9.6. G3000PW analytical gel permeation. Protein samples (100
Wl) were injected onto a G3000PW gel permeation column
(21.5U300 mm, Toso Haas) using a BioCad workstation (Perseptive
Biosystems) and eluted with 25 mM sodium phosphate bu¡er aug-
mented with 0.4 M NaCl and 0.02% NaN3 (pH 7.5). The column was
eluted at a £ow rate of 5 ml/min with fractions taken every 30 s.
Native molecular weight was determined by calibrating standard pro-
teins (bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa),
cytochrome c (17 kDa), aprotinin (6.5 kDa)) by their retention time
(absorbance 210 and 280 nm) and comparing the resulting calibration
curve to the retention time of the active protein.
2.9.7. C-18 reverse phase chromatography. To prepare puri¢ed
adociavirin samples for N-terminal sequencing, the protein was in-
jected onto a Dynamax C-18 column (4.6U300 mm, 5 Wm, 300 Aî ,
Rainin) and eluted with a linear gradient of 0^80% acetonitrile in H2O
(augmented with 0.1% TFA) over 5 CV (V25 ml) at a £ow rate of 0.8
ml/min. The eluate was monitored for absorbance at 210 nm and
fractions were collected by hand.
2.10. Electrophoresis
2.10.1. SDS-PAGE. SDS-PAGE was carried out using 18% poly-
acrylamide resolving gels, 4% polyacrylamide stacking gels and stand-
ard discontinuous bu¡er systems according to Laemmli [20] on a Bio-
Rad Mini Protean II apparatus. The gels (50U80U1 mm) were sub-
jected to electrophoresis at a constant current of 30 mA/gel at room
temperature with chilled electrode bu¡er.
2.10.2. Isoelectric focusing. soelectric focusing was carried out us-
ing a non-urea 5% polyacrylamide tube gel system on a Bio-Rad Mini
Protean II apparatus. Protein samples were focused at 4‡C in a pH
gradient of 3.5^9.5 using Bio-Rad ampholytes and the following volt-
age conditions: 500 V for 15 min followed by 750 V for 210 min. The
isoelectric point of the protein was determined by comparison to a
standard calibration using commercially available standard proteins
(IEF Mix II, Sigma).
2.10.3. PAS and silver staining. SDS-PAGE gels were stained for
protein using either Coomassie brilliant blue or a modi¢ed Merril
silver stain [21]. Gels were stained for glycoproteins by a periodic
acid Schi¡ (PAS)-based stain (glycoprotein detection kit, Sigma).
2.11. gp120 and CD-4 binding studies
To determine the a⁄nity of adociavirin for the HIV envelope pro-
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tein gp120, dot-blot assays were conducted as follows: (1) 10 Wl sam-
ples of either adociavirin or standard proteins (bovine globulin and
aprotinin as negative controls, horseradish peroxidase as a positive
control) were absorbed onto a PVDF membrane by capillary action.
(2) The protein-bound membrane was incubated overnight in a 1%
solution of BSA in PBS bu¡er. (3) The blocked membrane was
washed with TPBS for 20 min (U3). (4) The washed membrane was
incubated with a 1 Wg/ml solution of gp120-horseradish peroxidase
conjugate for 30 min. (5) The membrane was again washed with
TPBS for 20 min (U3). (6) The conjugate-bound membrane was
then incubated in a color development solution consisting of the per-
oxidase substrate 3-amino-9-ethylcarbazole (AEC) and 0.1% hydrogen
peroxide in TPBS until spots became visible on the membrane.
To determine the a⁄nity of adociavirin for the cellular receptor
CD4, dot-blot assays were conducted as follows: (1) 10 Wl samples
of either adociavirin or standard proteins (bovine globulin and apro-
tinin as negative controls, horseradish peroxidase as a positive con-
trol) were absorbed onto a PVDF membranes by capillary action. (2)
The protein-bound membranes were incubated overnight in a 1%
solution of BSA in PBS bu¡er. (3) The blocked membranes were
washed with TPBS for 20 min (U3). (4) The washed membranes
were then incubated with solution of 1 Wg/ml soluble CD4 (sCD4,
Advanced Biotechnologies) in PBS for 45 min. (5) The membranes
were again washed with TPBS for 20 min (U3). (6) The membranes
were then incubated with either rabbit anti-CD4 polyclonal antibodies
or a monoclonal antibody speci¢c to the gp120 binding site of CD4
(OKT4a or Q4120). (7) The membranes were again washed with
TPBS for 20 min (U3) and incubated with HRP-conjugated second-
ary antibodies, followed by a ¢nal washing in TPBS and incubation
with the chromogenic substrate AEC.
2.12. Mass spectroscopy
Matrix assisted laser desorption ionization-time of £ight (MALDI-
TOF) mass spectroscopy was done using a Kratos Kompact Maldi II
instrument (Shimadzu) using sinapinic acid as a matrix and trypsin
and BSA as internal standards. For the analysis of reduced adociavir-
in, L-mercaptoethanol (L-MCE) (2%) was added to the sample prior
to the addition of the matrix.
2.13. Amino acid analysis and sequencing
Adociavirin (500 Wg) was taken up in 8 M guanidine hydrochloride
and reduced by the addition of 10 Wl L-MCE. The protein was allowed
to react with the L-MCE for 1 h. Following reaction with L-MCE, a
10-fold molar excess of 4-vinylpyridine was added to the reaction
vessel and the mixture was blanketed with N2 and allowed to react.
After 2 h the reaction mixture was evaporated under N2 to remove
volatile L-MCE from the mixture. The mixture was then injected onto
a C-18 reverse phase column and eluted as described previously.
Pyridinylated adociavirin was digested by endoprotease Lys-C using
a 50:1 ratio of adociavirin to Lys-C (Boehringer Mannheim) in Tris-
HCl bu¡er (pH 8.5). The mixture was allowed to react for 18 h
followed by C-18 reverse phase chromatography to purify the peptide
fragments.
Amino acid analysis was performed using a Beckman Model 6300
amino acid analyzer according to manufacturer protocols. N-terminal
amino acid sequencing was performed on an Applied Biosystems
Model 477A sequencer according to manufacturer protocols.
3. Results and discussion
The bioassay-guided fractionation of aqueous extracts of
the marine sponge Adocia sp. resulted in the isolation of a
novel HIV-inhibitory protein named adociavirin. The protein
was puri¢ed to homogeneity by the sequential use of ethanolic
and ammonium sulfate precipitation followed by gel ¢ltration,
anion exchange and hydrophobic interaction chromatogra-
phy. The protein, homogenous by SDS-PAGE, had a molec-
ular weight of approximately 19 kDa (Fig. 1).
Analytical gel ¢ltration studies of adociavirin showed that
the protein was a homodimer in its native state with a molec-
ular radius equivalent to 37 kDa. In subsequent SDS-PAGE
and MALDI-TOF mass spectroscopy studies, the adociavirin
monomers (18.4 kDa) were shown to be linked through disul-
¢de bonds which were cleaved by L-MCE (Fig. 2A,B,C, re-
spectively). This disul¢de linkage between monomers was also
con¢rmed by MALDI-TOF analysis of adociavirin following
reduction and modi¢cation of Cys residues with 4-vinylpyri-
dine (data not shown).
Adociavirin had an isoelectric point of 4.0 by native iso-
electric focusing and was not stained in the PAS staining
system for glycoproteins, thereby indicating that the protein
was not glycosylated.
Following pyridinylation of the reduced cysteine residues
with 4-vinylpyridine and C-18 reverse phase puri¢cation of
adociavirin, the protein was characterized by both amino
acid analysis (Table 1) and by N-terminal Edman degradation
sequence analysis. Protease cleavage of the 4-vinylpyridine
modi¢ed protein with Lys-C endoprotease, and isolation
and sequencing of the resulting peptide fragments, was also
attempted but yielded little additional sequence information.
Adociavirin was a very hydrophobic protein, failing to elute
from C-18 until a level of 75% acetonitrile was reached. Cer-
tain peptide fragments of the pyridinylated protein, however,
could only be eluted from the column by the use of hot iso-
propanol. Despite this problem, enough peptide fragments
were recovered and sequenced to con¢rm the 41 amino acid
N-terminal sequence as follows: H2N-Ser-Asn-Gly-Glu-Ile-
Phe-Val-Asn-Ser-Ile-Gly-Asn-Leu-Glu-Lys-Ile-Phe-Ile-Ala-Ser-
Met-Asp-Asp-Cys-Pro-Asn-Asp-Lys-Arg-Arg-Leu-Thr-Leu-
Glu-Glu-Ala-Thr-Ala-Val-Gln-Asp-.
Database searches using this 41 amino acid sequence as a
seed for the GCG search program determined that no signi¢-
cant homology (s 20%) existed between adociavirin and any
of the amino acid or translated DNA sequences in the data-
base, thereby indicating that it is a novel protein.
Examination of the stability of partially puri¢ed adociavirin
indicated that the HIV-inhibitory activity of the protein was
stable for periods of one month when stored at 4‡C, 320‡C or
370‡C but was reduced by approximately 50% when stored at
room temperature for a month. In addition, the anti-HIV
activity of adociavirin was stable in the pH range 6^8. How-
ever, the addition of either the chelating agent EDTA or the
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Fig. 1. SDS-PAGE analysis of various puri¢cation stage of adocia-
virin. A 15% acrylamide gel (50U80U1 mm) was electrophoresed at
25 mA and stained with Coomassie brilliant blue. Lane 1, molecular
mass standards; lane 2, crude aqueous extract of Adocia sp.; lane 3,
ethanolic supernatant fraction; lane 4, ammonium sulfate precipi-
tate; lane 5, Sephadex G-100 column fraction; lane 6, anion ex-
change column fraction; lane 7, phenyl-ether column fraction.
B.R. O’Keefe et al./FEBS Letters 431 (1998) 85^90 87
reducing agent dithiothreitol to the storage bu¡er (50 mM
sodium phosphate, pH 7.5) decreased the activity of adocia-
virin by 75%.
Adociavirin bound both to the cellular receptor CD4 and
the viral envelope glycoprotein gp120 but not to control pro-
teins (horseradish peroxidase and BSA) in dot-blot assays
(data provided to the reviewers). Studies on a similarly
‘dual-binding’ anti-HIV peptide named T-22 ([Tyr5;12,Lys7]-
polyphemusin II), have also been reported, but this argi-
nine-rich 2 kDa peptide has no homology to adociavirin
[22]. The speci¢c interactions between adociavirin and CD4
and gp120 will require further molecular studies.
Conventional anti-HIV-induced cytopathicity assays using
CEM-SS lymphoblastoid cells [12] were used to monitor the
progress of the puri¢cation of adociavirin. Adociavirin con-
taining samples consistently displayed activity in the 10^100
nM range in this assay system. Furthermore, a multipa-
rameter assay [13] demonstrated that adociavirin not only
inhibited the cell killing associated with HIV infection but
also decreased the production of infectious virions and the
accumulation of viral reverse transcriptase activity in the cell
culture supernatants (Fig. 3).
Additional studies of the time course of adociavirin activity
against incipient HIV-1 infection showed a 50% reduction of
activity if addition of the protein was delayed 2 h after virus
addition. The decrease in cytoprotection was mirrored by an
increase in supernatant accumulation of reverse transcriptase
activity (Fig. 4). These studies provided further con¢rmation
that the protein interacts very early in the infection process,
most likely at the level of viral binding or fusion. In subse-
quent cell-cell fusion assays, wherein cells chronically infected
with HIV-1 were allowed to fuse with uninfected cells, ado-
ciavirin inhibited cell-cell fusion (as determined by the number
of syncytia) with an EC50 of 10 nM (Fig. 5). Taken together,
these two studies strongly suggest that adociavirin is most
likely a surface-active HIV-1 inhibitory protein which binds
to either viral and/or cell surface molecules.
Adociavirin displayed potent activity against a broad range
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Fig. 2. Analysis of the dimeric nature of adociavirin. A: SDS-PAGE analysis of reduced and native adociavirin. Native adociavirin and adocia-
virin reduced by the addition of L-mercaptoethanol were electrophoresed on a 15% acrylamide gel (50U80U1 mm) at 25 mA and stained with
Coomassie brilliant blue. B: MALDI-TOF mass spectroscopic analysis of native adociavirin using siapinic acid as a matrix and trypsin and
BSA as external standards. C: MALDI-TOF mass spectroscopic analysis of adociavirin reduced by the addition of 2% L-mercaptoethanol, ma-
trix and standards the same as above.
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of laboratory-adapted strains and primary isolates of HIV-1,
as well as HIV-2 (Table 2). Adociavirin appeared most potent
in protecting macrophage cell cultures from the cytopathic
e¡ects of the virus with EC50 values in the low nanomolar
range (0.4^3.0 nM). The protein appeared less active in T-cell
cultures, with EC50 values in the range of 30^60 nM and was
least active in protecting PBLs from the virus with EC50s two
to three orders of magnitude weaker than in macrophage
cultures (97 to s 400 nM). Of particular interest were the
simultaneous assays performed using the dual-tropic HIV-1
strains 89.6 and ADA. In this assay, PBL and macrophage
cells isolated from the same leukopack were infected with the
dual-tropic viruses and simultaneously treated with various
dilutions of adociavirin. The results con¢rmed earlier assays
in which adociavirin exhibited signi¢cantly better e⁄cacy in
macrophage cultures; in this case approximately 250-fold bet-
ter.
The apparent cell-line tropism displayed by adociavirin may
be indicative of some form of preferential interaction with the
surface of macrophage cells or with the viral surface constit-
uents that preferentially interact with macrophage cells. Re-
cent reports have indicated that certain seven-transmembrane
domain, G-coupled cell surface receptors (i.e. CKR-5,
CXCR4) in the chemokine receptor family are involved with
the speci¢c tropisms displayed by HIV-1 subtypes (for recent
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Fig. 5. E¡ect of adociavirin on the inhibition of cell-cell fusion. Un-
infected CEM-SS cells were co-cultured with CEM-SS cells chroni-
cally infected with HIV-1RF in the presence of various concentra-
tions of adociavirin for 72 h. After incubation the number of
syncytia (b) was determined microscopically. The results represent
the mean of quadruplicate samples, graphically represented as the
percent of the non-drug-treated controls.
Fig. 4. Time course of the protective e¡ects of adociavirin. E¡ect of
delayed addition of 1.3 Wg/ml adociavirin on HIV-1RF infected (b)
and uninfected (a) CEM-SS cells analyzed after 6 days in culture
using the XTT assay. Reverse transcriptase activity (open bars) was
also measured at each time point. The dotted line indicates un-
treated virus-infected cell controls and the dashed line indicates un-
treated uninfected cell controls.
Fig. 3. Multiparameter analysis of the anti-HIV activity of adocia-
virin. E¡ect of adociavirin on uninfected (a) and HIV-infected (b)
CEM-SS cells assessed after 6 days in culture using (A) cellular via-
bility, (B) metabolic activity, (C) total DNA content, (D) superna-
tant reverse transcriptase activity (R) and synthesis of infectious vi-
rions (F). Values for infected cultures represent the mean of
quadruplicate samples (S.E.M.9 15%), while uninfected values rep-
resent the mean of duplicate samples. All points are graphically rep-
resented as the percent of the uninfected, non-drug-treated control
values.
Table 1
Amino acid analysis of adociavirin
Amino acid Residues Molar %
Asx 17 10.5
Thr 8 5.0
Ser 8 5.0
Glx 13 8.0
Gly 18 11.2
Ala 14 8.7
Cysa 2 1.2
Val 9 5.6
Met 2 1.2
Ile 11 6.8
Leu 11 6.8
Tyr 5 3.1
Phe 8 5.0
His 1 0.6
Lys 9 5.6
Arg 7 4.3
Pro 5 3.1
aDetermined as pyridylethylcysteine.
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reviews, see [23,24]). Whether or not adociavirin’s activity is
related to speci¢c interactions with any of these receptors is a
question that will be addressed in further studies.
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Table 2
ANti-HIV activity of adociavirin
Cell type Virus strain EC50 (nM) IC50 (nM)
Macrophagea ADA 0.4 s 405
Macrophagea 89.6 0.4 s 405
Macrophage Ba-L 3.0 319
Macrophage ADA 2.0 319
PBMCa ADA 97 s 405
PBMCa 89.6 111 s 405
PBMC WEJO 278 s 405
PBMC TEKI 119 s 405
PBMC SLKA 122 s 405
CEM-SS HIV-2 ROD 100 270
CEM-SS IIIB 59 s 405
CEM-SS RF 35 s 405
MT2 IIIB n.p. 205
MT2 RF 32 221
H9 IIIB s 405 s 405
aAssays run simultaneously from the same leukopack.
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